Can a new Immune-Boosting drug shrink advanced solid tumors?
NCT ID NCT07793942
First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread and cannot be removed by surgery. The main goals are to check the safety of the drug and how many participants see their tumors shrink or disappear. The study will also measure how long any response lasts and how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MK-2010 (also known as LM-299), an investigational biologic given by IV infusion, designed to help the immune system fight cancer. It is tested alone or with other treatments like pembrolizumab, chemotherapy, and belzutifan.
- What this could lead to
- If MK-2010 proves safe and effective, it could offer a new treatment option for people with advanced solid tumors, potentially shrinking or slowing the growth of cancers that have spread.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or may cause side effects. The results will need confirmation in larger studies before it becomes a standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 480 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Has radiographically measurable disease per protocol * If to receive oral study treatment, has the ability to swallow and retain oral medication and does not have gastrointestinal abnormalities that may alter absorption * Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if diagnosed with HIV * Has adequate organ function per protocol Exclusion Criteria: * Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease if diagnosed with HIV * Has a history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder * Has hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis * Has a history of confirmed inflammatory bowel disease * Has a serious active nonhealing wound, ulcer, and/or bone fracture * Has a history of myocarditis or cardiomyopathy * Has a history of or current severe cardiovascular and cerebrovascular diseases * Is currently receiving any anticoagulants * Has a diagnosis of immunodeficiency * Has a known additional malignancy that is progressing or required active treatment within the past 3 years * Has known active central nervous system metastases and/or carcinomatous meningitis * Has active autoimmune disease that required systemic treatment in the past 2 years (hormonal supplementation \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed) * Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD * Has a history of stem cell/solid organ transplant * Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, Dose-Escalation and expansion phase I/IIa clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy of SGT003 in patients with advanced solid tumors
- Can a new drug shrink advanced solid tumors?
- Can a radioactive 'Smart Bomb' target tough tumors?
- Can a drug duo outsmart a common cancer mutation?
- Can a new pill shrink advanced solid tumors?
- Can a drug duo shrink Hard-to-Treat tumors?